Chengdu Olymvax Biopharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Shaowen Fan
Chief executive officer
CN¥713.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 15yrs |
| CEO ownership | 3.9% |
| Management average tenure | no data |
| Board average tenure | 8.6yrs |
Recent management updates
Recent updates
CEO
Shaowen Fan (71 yo)
15yrs
Tenure
CN¥713,500
Compensation
Mr. Shaowen Fan is Chairman of the Board & GM of Chengdu Olymvax Biopharmaceuticals Inc. from January 2010. Mr. Fan joined the Chengdu Olymvax Biopharmaceuticals Inc. in 2010.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 15yrs | CN¥713.50k | 3.86% CN¥ 165.5m | |
| Director | 11.6yrs | CN¥42.00k | 0.014% CN¥ 591.6k | |
| Chairman of Supervisory Board | 8.6yrs | no data | 6.38% CN¥ 273.4m | |
| Executive Deputy GM & Vice Chairman of the Board | 15yrs | CN¥633.20k | 7.53% CN¥ 322.9m | |
| Director | 2.7yrs | CN¥42.00k | 1.64% CN¥ 70.4m | |
| Director | 15yrs | CN¥602.00k | 0.15% CN¥ 6.5m | |
| Employee Representative Director | 2.7yrs | CN¥195.00k | 0.067% CN¥ 2.9m | |
| Independent Director | 5.8yrs | CN¥83.90k | no data | |
| Supervisor | 2.7yrs | no data | 0.20% CN¥ 8.6m |
8.6yrs
Average Tenure
61yo
Average Age
Experienced Board: 688319's board of directors are considered experienced (8.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/11 09:38 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chengdu Olymvax Biopharmaceuticals Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Yupeng Jiao | China Merchants Securities Co. Ltd. |
| Feifei Xu | China Merchants Securities Co. Ltd. |